Protein kinase inhibitor
Showing 1 - 25 of >10,000
Cancer Trial in Changsha (Protein Kinase Inhibitor)
Recruiting
- Cancer
- Protein Kinase Inhibitor
-
Changsha, Hunan, ChinaCentral South University
Jun 23, 2022
Hepatocellular Carcinoma Trial in Taichung (Xiang Sha Liu Jun Zi Decoction dry powder, XSLJZ Placebo)
Enrolling by invitation
- Hepatocellular Carcinoma
- Xiang Sha Liu Jun Zi Decoction dry powder
- XSLJZ Placebo
-
Taichung, 西屯區, TaiwanChina Medical University hospital
Dec 9, 2021
Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma Plexiform
-
Shanghai, China
- +1 more
Jan 13, 2023
Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)
Active, not recruiting
- Neurofibromatosis 1
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency Trial in Providence (Palbociclib Oral
Not yet recruiting
- Advanced Breast Cancer
- +6 more
- Palbociclib Oral Product
- TAS-116
-
Providence, Rhode IslandLifespan Cancer Institute
Feb 1, 2023
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor Trial in United States (CDK Inhibitor
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- CDK Inhibitor AT7519
- +3 more
-
Washington, District of Columbia
- +5 more
Oct 18, 2022
Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib
Enrolling by invitation
- Hepatocellular Carcinoma Non-resectable
- +3 more
- lenvatinib + sindilimab/carrelizumab
- TACE
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
May 23, 2022
Lung Cancer Trial in Carlsbad, Cleveland (ISIS 3521, carboplatin, paclitaxel)
Completed
- Lung Cancer
- ISIS 3521
- +2 more
-
Carlsbad, California
- +1 more
Dec 1, 2022
Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,
Recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Acalabrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 Trial
Not yet recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- +3 more
- Biopsy
- +8 more
- (no location specified)
Jan 13, 2023
Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)
Recruiting
- Liver Neoplasms
- Tislelizumab plus tyrosine kinase inhibitor
-
Beijing, Beijing, China302 Hospital
Sep 22, 2023
Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial
Recruiting
- Advanced Malignant Solid Neoplasm
- +8 more
- Imatinib Mesylate
- Ipilimumab
-
Houston, TexasM D Anderson Cancer Center
Aug 1, 2022
Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- combination therapy with no MEKi
- +3 more
- (no location specified)
Nov 29, 2022
Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals
Not yet recruiting
- Preterm Labor
- (no location specified)
May 9, 2023
CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)
Recruiting
- CML
- Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
-
Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, ArgentinaFUNDALEU
Jun 29, 2023
Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase
Recruiting
- Liver Transplant
- PVHA or TACE
-
Shanghai, Shanghai, ChinaThe value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022
Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)
Not yet recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
- (no location specified)
Aug 1, 2023
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung
Active, not recruiting
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma
- +5 more
-
Sacramento, California
- +17 more
Aug 2, 2022
Advanced Solid Tumors Trial in Worldwide (MSC2490484A (M3814), Fractionated RT, Cisplatin)
Completed
- Advanced Solid Tumors
- MSC2490484A (M3814)
- +2 more
-
Fresno, California
- +25 more
Apr 6, 2022
Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)
Not yet recruiting
- Acute Myeloid Leukemia
- Lymphoma, Mantle-Cell
- (no location specified)
Dec 22, 2022